Watch 'Financial #Barriers to Oral #Cancer Therapies' now: bit.ly/3TwK2N2

Tune-in as Aimee Hoch GVHHealth discusses how and when to screen patients. Plus, discover helpful resources to better support patients’ financial needs. #podcast #breastcancer #oncology

This just in at #ACCCNOC . Carmen Guerra, MD, MSCE, FACP, explores efforts to increase diversity in cancer clinical trials. Her advice? 'Don't assume, just ask!'

Access the ACCC-ASCO 'Just Ask' Training Program now: bit.ly/3Vqy1dQ

Published in Journal of Clinical Oncology, an updated assessment of the safety & efficacy of a selective RET inhibitor in pts w/ RET fusion–positive #NSCLC treated in the phase I/II LIBRETTO-001 trial. #lcsm

Learn more: e.lilly/3CjBphW

Published in The Lancet Oncology, learn more about tumor-agnostic efficacy & safety of a selective RET inhibitor in pts w/ RET fusion-positive solid tumors other than lung or thyroid. #CancerResearch

View the results: e.lilly/3EuOfN7

Maryam Lustberg MD MPH @yalecancer @yalemed & Sandra Cuellar UIC Pharmacy join the CANCER BUZZ vodcast: bit.ly/3CFSRPa Tune in as our experts examine challenges with oral anti-cancer therapies & provide methods to better support patients: bit.ly/3EobaJY #cancer #podcast

'We see the disparities and want to change them.” A new Lilly education campaign focuses on Black women and their #breastcancer journey. Read about this innovative campaign: e.lilly/3SFMxw3 #WeAreLilly

Thank you to everyone who joined us in Houston & online for an excellent #SOHO22 !

Developing innovative new medicines for people living w/ #cancer is at the center of what we do.

To learn more about our ongoing #hematology research & pipeline, visit: e.lilly/3UA9na7

Clinical trials help develop new treatments that may improve patient lives. In collaboration with Eli Lilly and Company, we feel trial diversity is critical to advancing health equity & ensuring treatments may benefit all who use them. Find trials in #CLL bit.ly/3ejyZrf #BCAM2022

Join us at #SOHO22 - We're presenting results from the phase 1/2 BRUIN study, investigating a highly selective, reversible (non-covalent) #BTKi in previously treated #MantleCellLymphoma (MCL). #lymsm

View the presentation: e.lilly/3SbqLR4

At #SOHO22 , we’re presenting results from the phase 1/2 BRUIN trial, investigating a highly selective, reversible (non-covalent) #BTKi in previously treated #CLL / #SLL .

View the presentation: e.lilly/3r3Ydgm

#leusm #lymsm

We’re excited to join the #hematology community in Houston for Society of Hematologic Oncology (SOHO)’s 10th annual meeting! #SOHO22

If attending, be sure to stop by booth 150 & meet our medical team.

To learn more about our latest #bloodcancer research & pipeline, visit: e.lilly/3UA9na7

See results from a retrospective study investigating real-world overall survival in patients w/ metastatic #ColorectalCancer receiving an EGFR inhibitor as 2nd-line or 3rd-line treatment. #crcsm

Published in Future Oncology: e.lilly/3S7YIBp

Published in Advances in Therapy: See results from a retrospective cohort study on patients in Japan w/ recurrent #MantleCellLymphoma assessing real-world outcomes after BTK inhibitor discontinuation. #lymsm #MCL

View the study results: e.lilly/3Lgi4lJ

Thank you to everyone who joined us for a memorable #ESMO22 ! We head home inspired by your commitment to advancing #CancerResearch & elevating patient care.

Visit the Loxo@Lilly virtual exhibit to view the research we presented at this year's meeting: e.lilly/3qqC9MI

See updated safety, pharmacokinetics and antitumor activity data from the ongoing phase 3 BREAKWATER study evaluating a BRAFi and EGFRi combination with or without chemotherapy in patients with metastatic BRAFV600E colorectal cancer #ESMO22 LBA26 bit.ly/3ROGrsG

RET gene fusions occur in 1-2% of #NSCLC . Timely & accurate detection methods are needed to identify pts that may benefit from RET-targeted therapy.

At #ESMO22 , we’re sharing a literature review & comparison of RET detection by FISH testing.

Learn more: e.lilly/3eB9cuH

At #ESMO22 – SWOG Cancer Research Network is presenting exploratory analysis from Lung-MAP S1800A, a study investigating OS w/ a VEGFR2 inhibitor + a PD1 inhibitor in pts w/ advanced #NSCLC following progression on prior ICI & platinum chemotherapy. #LCSM

View presentation: e.lilly/3DcaGWw

At #ESMO22 , we’re sharing exploratory posthoc analysis from the LIBRETTO-001 trial, assessing safety and efficacy outcomes in a subset of #NSCLC pts that continued treatment w/ a selective RET inhibitor beyond disease progression. #lcsm

View presentation: e.lilly/3S96njd

Join us at #ESMO22 - We’re presenting updated efficacy and safety analysis with more mature follow-up from LIBRETTO-001, a trial investigating a selective RET inhibitor in patients with RET-mutant medullary #thyroidcancer .

View the presentation: e.lilly/3RSF8ZO